Phase 1/2 study of peptide vaccination associated with CT-GM-01, a galactomannan oligomer that inhibits galectin-3, in patients with advanced metastatic melanoma.

Trial Profile

Phase 1/2 study of peptide vaccination associated with CT-GM-01, a galactomannan oligomer that inhibits galectin-3, in patients with advanced metastatic melanoma.

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Galactomannan C (Primary) ; MAGE-A3 peptide vaccine (Primary) ; NA17-A2 peptide vaccine (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jan 2014 Status changed from recruiting to suspended, as reported by a Galectin Therapeutics media release.
    • 29 Nov 2012 New source identified and integrated (ClinicalTrials.gov record NCT01723813).
    • 11 Oct 2012 New source identified and integrated (European Clinical Trials Database record EudraCT2010-018638-29).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top